[慢性脑缺血患者焦虑症的药物治疗]
[Pharmacotherapy of anxiety disorders in patients with chronic cerebral ischemia].
作者信息
Vorob'eva O V, Rusaya V V
机构信息
Sechenov First Moscow State Medical University, Moscow, Russia.
出版信息
Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(12. Vyp. 2):49-55. doi: 10.17116/jnevro201611612249-54.
AIM
To compare the effects of the daytime anxiolytic adaptol and the tranquilizer/nootropic drug noophen on target symptoms related to anxiety spectrum disorders in patients with chronic cerebral ischemia (CCI).
MATERIAL AND METHODS
Sixty-two patients with CCI and comorbid anxiety spectrum disorders were randomized to adaptol group (n=29) and noophen group (n=33). Results of treatment were assessed with CGI, MFI-20, HADS-A and HADS-D, MMSE.
RESULTS AND CONCLUSION
Both drugs showed the comparable efficacy and speed of achievement of anxiolytic effect. Anxiety symptoms were stopped in 79.0% of the patients. Adaptol was superior to noophen in regard to nonspecific somatic symptoms (р=0.037). Asthenia and sleep disorders have decreased significantly in the noophen group. Use of target symptoms in the individual choice of anxiolytic therapy in patients with anxiety spectrum disorders associated with CCI can increase treatment efficacy.
目的
比较日间抗焦虑药物阿得尔和镇静益智药物脑复新对慢性脑缺血（CCI）患者焦虑谱系障碍相关靶症状的影响。
材料与方法
62例患有CCI合并焦虑谱系障碍的患者被随机分为阿得尔组（n = 29）和脑复新组（n = 33）。采用临床总体印象量表（CGI）、医学结局研究简明健康调查问卷20项版（MFI - 20）、医院焦虑抑郁量表焦虑亚量表（HADS - A）、医院焦虑抑郁量表抑郁亚量表（HADS - D）、简易精神状态检查表（MMSE）评估治疗结果。
结果与结论
两种药物在抗焦虑疗效和起效速度方面相当。79.0%的患者焦虑症状得到缓解。在非特异性躯体症状方面，阿得尔优于脑复新（p = 0.037）。脑复新组的乏力和睡眠障碍显著减轻。在与CCI相关的焦虑谱系障碍患者的抗焦虑治疗中，根据个体靶症状选择用药可提高治疗效果。
Zotero 插件